Previous 10 | Next 10 |
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial results for the fourth quarter and full year 2019 and provided 2020 financial guidance. Preliminary, unau...
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the successful completion of patient enrollment in the aMAZE™ clinical trial. In addition, the company announced that it has rece...
The SPDR S&P 500 Trust's (SPY) rally to new highs has been a boon to big-cap investors, but the Russell 2000 has yet to eclipse its 2018 highs, and that's left small-cap investors envious. Fortunately, small caps' under-performance may not last much longer. Over the past decade, the Russel...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming 38th Annual JP Morgan Healthcare Conference in San Francisco. AtriCure&...
AtriCure, Inc. (Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Karen Prange and Daniel Florin have been named to its Board of Directors. Ms. Prange was most recently Executive Vice Presid...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Piper Jaffray 31 st Annual Healthcare Conference in New York City. Atr...
AtriCure Inc (NASDAQ:ATRC) Q3 2019 Earnings Conference Call Oct 30, 2019, 4:30 PM ET Company Participants Lynn Lewis - Gilmartin Group Mike Carrel - President and Chief Executive Officer Andrew Wade - Senior Vice President and Chief Financial Officer Conference Call Participan...
Image source: The Motley Fool. AtriCure Inc (NASDAQ: ATRC) Q3 2019 Earnings Call Oct 30, 2019 , 4:30 p.m. ET Operator Continue reading
AtriCure (NASDAQ: ATRC ): Q3 GAAP EPS of -$0.25 beats by $0.06 . More news on: AtriCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Worldwide revenue of $56.6 million – an increase of 13.4% year over year U.S. revenue of $46.1 million – an increase of 16.0% year over year International revenue of $10.5 million – an increase of 3.1% year over year AtriCure, Inc. ( Nasdaq: ATRC ), a l...
News, Short Squeeze, Breakout and More Instantly...
2024-07-31 08:00:12 ET Rick Wise from Stifel Nicolaus issued a price target of $26.00 for ATRC on 2024-07-31 06:57:00. The adjusted price target was set to $26.00. At the time of the announcement, ATRC was trading at $22. The overall price target consensus is at $56.00 w...
Worldwide revenue of $116.3 million – an increase of 15.2% year over year Positive cash flow generation of $8.1 million in second quarter 2024 AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), l...
CFSB Bancorp Inc. (CFSB) is expected to report for Q4 2024 Big 5 Sporting Goods Corporation (BGFV) is expected to report $-0.48 for Q2 2024 Canadian Pacific Kansas City Limited (CP) is expected to report $0.74 for Q2 2024 Captivision Inc. (CAPT) is expected to report for quarter end 2...